12:00 AM
Apr 15, 2013
 |  BC Week In Review  |  Company News  |  Deals

Isis Pharmaceuticals, Roche deal

Roche and Isis partnered to develop therapies to treat Huntington's disease (HD). Isis will use its antisense oligonucleotide technology to discover and develop new and existing therapeutics that block production of all forms of the huntingtin (HTT) protein, as well as production of the disease-causing forms...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >